Oruka Therapeutics said it will report Week 16 data from its ongoing EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis on April 27, 2026. The announcement is a routine clinical-update milestone with no trial results disclosed yet. Impact on the stock is likely limited until the data readout is released.
Oruka Therapeutics said it will report Week 16 data from its ongoing EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis on April 27, 2026. The announcement is a routine clinical-update milestone with no trial results disclosed yet. Impact on the stock is likely limited until the data readout is released.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
